Temple City, CA (PRWEB) June 14, 2013
Fulgent Therapeutics LLC, a CLIA Certified Laboratory, announces the inclusion of BRCA1 and BRCA2 analysis to its Hereditary Cancer Panel. Fulgent Therapeutics is excited to add these key targets, making it the most comprehensive test for cancer risk assessment available.
Fulgent Therapeutics Hereditary Cancer Panel detects mutations in 49 known cancer predisposition genes, now including BRCA1 and BRCA2. “We use well defined processes, robust bioinformatics, and Next Generation Sequencing to provide our clients with a comprehensive look at a true myriad of genes,” according to Dr. Harry Gao, Lab Director for Fulgent Therapeutics.
Personalized medicine demands that we examine diseases in new ways and deploy innovative tools to view all angles of the patient’s health and potential diseases. Fulgent Therapeutics Hereditary Cancer Panel provides patients and physicians with the information to assess their risks and guide their care. “Making molecular diagnostics more comprehensive and at the same time more affordable is our goal,” says Dr. Gao.
Fulgent Therapeutics president, Ming Hsieh stated, “We agree with the Supreme Court’s decision and we look forward to providing physicians with better tools and more options to help their patients."
Fulgent Therapeutics is currently working on panels for more than just cancer. The Next Generation panels for many inherited disease including cardiology, pediatrics, and neurology will provide physicians with more information than previously available.
The release date for the Hereditary Cancer Panel, including BRCA1 and BRCA2, will be available July 8, 2013. Fulgent Therapeutics anticipates that it will provide another first to the industry by getting the 49-gene panel’s price under $3,000.
Additional information: info(at)fulgent-therapeutics(dot)com or 626-350-0537 x106.
About Fulgent Th
Copyright©2012 Vocus, Inc.
All rights reserved